Sitagliptin ameliorates hypoxia-induced damages in endometrial stromal cells: an implication in endometriosis

Ying Li, Xiaolin Lv, Mei Jiang, and Zhili Jin

Department of Obstetrics and Gynecology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou City, Liaoning Province, China; Department of Rheumatology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou City, Liaoning Province, China

ABSTRACT

Hypoxia-induced damage in endometrial stromal cells (ESCs) is an important event in the pathological progression of Endometriosis. It is reported that significant inflammation is induced by hypoxia in ESCs, mediated by several inflammatory pathways, processes, or factors. Sitagliptin, an important member of the dipeptidyl peptidase-4 (DPP-4) inhibitors family and has been widely used for the management of type 2 diabetes. It has been recently reported to exert significant anti-inflammatory effects. Here, we aim to assess whether Sitagliptin possesses a protective effect against hypoxia-induced damages in ESCs. Our findings indicate that exposure to hypoxia significantly increased oxidative stress in ESCs by increasing the production of reactive oxygen species (ROS) and decreasing the levels of reduced glutathione (GSH), which was ameliorated by Sitagliptin. Additionally, the excessively produced inflammatory mediators, including tumor necrosis factor (TNF)-α, interleukin (IL)-6, monocyte chemoattractant protein-1 (MCP-1), cyclooxygenase-2 (COX-2), prostaglandin E2 (PGE₂), and high mobility group box (HMGB)-1, in hypoxia-treated HESCs were pronouncedly repressed by Sitagliptin. The activated p38 mitogen-activated protein kinases (MAPK) pathway was observed in hypoxia-stimulated HESCs, then greatly inhibited by the introduction of Sitagliptin. Lastly, hypoxia-induced phosphorylation and degradation of IκBα, as well as the upregulation of nuclear factor kappa-β (NF-κB) p65 and increased transcriptional activity of NF-κB, were dramatically abolished by Sitagliptin. Collectively, Sitagliptin ameliorated hypoxia-induced damages in ESCs by suppressing the inflammation.

INTRODUCTION

Endometriosis is a common gynecological disease in women of childbearing age. It is mainly characterized by endometrium located outside the uterine cavity, the main clinical symptoms of which are chronic pelvic pain, infertility, and dysmenorrhea [1]. According to the theory proposed by Sampson [2], exfoliated endometrial tissue loses its blood supply and is exposed to hypoxia, which plays an important role in inducing the development of Endometriosis.

It is reported that the expression level of hypoxia-inducible factor (HIF)-α can be elevated by the activated platelets, which effectively triggers the hypoxic state of endometrial stromal cells [3]. Once the oxygen supply is disrupted or declined, the survival of cells under hypoxia is facilitated by multiple adaptive signals produced by the organism. However, under a sustained hypoxia condition, the hypoxia-mediated gene regulatory network is triggered, subsequently changing the cellular function and behavior which finally contributes to the irreversible processes [4].

In Endometriosis patients, cyclooxygenase-2 (COX-2), a rate-limiting enzyme for the synthesis of prostaglandin E2 (PGE₂), is reported to be significantly upregulated in the endometrial epithelium, endometrial stroma, and peritoneal fluid, mainly induced by hypoxia [5]. The production of PGE₂, an important inflammatory mediator, can be facilitated by the overexpressed COX-2 in Endometriosis [5]. HIF-α is a key mediator for the adaptive hypoxia environment and is highly regulated by the cellular oxygen tension, the overexpression of which is the biomarker for hypoxia [4]. Wu reported that the function of dual-...
specificity phosphatase-2 (DUSP2) could be blocked by HIF-α, which induces the excessive production of COX-2 and the activation of p38 MAPK. Consequently, the development of ectopic endometrium is facilitated [6].

Apart from COX-2, the high mobility group box (HMGB)-1 is another inflammatory mediator reported to be involved in the development of Endometriosis [7]. In addition, the nuclear factor-κB (NF-κB) pathway, an important inflammatory signaling pathway, mediates the excessive release of HIF-α and finally triggers the development of Endometriosis [3]. As the inducing factor for inflammation, oxidative stress is reported to be closely associated with the development of Endometriosis [8]. Developing specific inhibitors against NF-κB and oxidative stress-mediated inflammation might be an effective strategy for the treatment of Endometriosis.

Sitagliptin is a promising dipeptidyl peptidase 4 (DDP-4) inhibitor developed by MERCK for the treatment of type II diabetes. It controls blood glucose by elevating the level of active islet hormones, such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulin stimulating polypeptide (GIP) [9]. Recently, it has been reported that Sitagliptin exerts significant anti-inflammatory actions in vascular endothelial cells, renal tissues of diabetic animals, and genetic obesity mice. Here, we proposed to explore the beneficial effects of Sitagliptin on hypoxia-induced damages in endometrial stromal cells to verify its potential therapeutic property on Endometriosis.

Materials and methods

Isolation of human endometrial stromal cells (HESCs), treatment, and hypoxia

Fresh endometrial tissues were collected and used to extract HESCs. In brief, following mincing tissues, cells were dispersed using the HBSS buffer supplemented with 25 mM HEPES, penicillin/streptomycin, 2 mg/ml collagenase, and 0.2 mg/ml DNase. After incubation at 37°C for 20 min, cells were separated by filtration through a 70 μm sieve and the stromal cells remained in the filtrate, followed by centrifugation, and resuspension in Ham’s F-12/Dulbecco’s minimal essential medium supplemented with penicillin/streptomycin and 10% FBS, and cultured in 5% CO₂ at 37°C. For the induction of hypoxia, HESCs were cultured in a modular incubator chamber (Billups-Rothenberg, California, USA) with hypoxic air (1% O₂, 5% CO₂, 94% N₂) at 37°C.

Release of lactate dehydrogenase (LDH)

The CytoTox-ONE™ kit (Promega, Wisconsin, USA) was utilized to determine the LDH release of HESCs. In brief, after collecting the supernatant of HESCs, the supernatant was placed in a black fluorescence plate and the CytoTox-ONE™ reagent was added for 10 min incubation, followed by adding the stop solution to terminate the reaction. Lastly, a microplate reader (BMG LABTECH, Offenburg, Germany) was utilized to measure the absorbance at 560/590 nm for the calculation of LDH release [10].

Dichloro-dihydro-fluorescein diacetate (DCFH-DA) staining

HESCs were seeded on a 96-well microplate and incubated for 24 h. Then 10 μM DCFH-DA dissolved in serum-free medium was added into each well, followed by 30 min incubation. After washing with the serum-free medium, a microplate reader (BMG LABTECH, Offenburg, Germany) was utilized to measure the absorbance at 488/525 nm [11].

Measurement of reduced GSH

The supernatant of HESCs was collected and the concentration of reduced GSH was determined using the method described by Beutler [12].

Real-time PCR

After isolating total RNAs from HESCs using the TRIzol reagent (Sigma-Aldrich, California, USA), cDNA was obtained by transcription from a 2 μg sample of RNA with a PrimeScript RT Reagent Kit (Takara, Tokyo, Japan). The RT-PCR was conducted with a 7500 Real-Time PCR System (ABI, California, USA) using the SYBR-Green dye (ABI, California, USA). Lastly, the gene expressions were
calculated utilizing the $2^{-\Delta\Delta Ct}$ method following being normalized with GAPDH.

**Western blot analysis**

After isolating total proteins from HESCs or nucleus with the lysis buffer, a BCA kit (Abcam, Cambridge, UK) was utilized to determine the concentration of proteins, followed by loading the proteins into the 12% SDS-PAGE. After separation, proteins in the gel were transferred onto the PVDF membrane (Abcam, Cambridge, UK), followed by incubation in the TBST buffer containing the primary antibody against COX-2 (1:1000, GeneTex, Texas, USA), p-p38 (1:2000, GeneTex, Texas, USA), p-IκBα (1:500, GeneTex, Texas, USA), IκBα (1:3000, GeneTex, Texas, USA), NF-κB p65 (1:3000, GeneTex, Texas, USA), or Tubulin (1:8000, GeneTex, Texas, USA). After incubating at 4°C overnight, the membrane was incubated with the secondary antibody (1:2000, GeneTex, Texas, USA) at room temperature for 90 min. Lastly, the ECL solution was utilized to expose the membrane and the expression of proteins was quantified using the Image J software [13].

**ELISA assay**

The secretions of TNF-α, IL-6, MCP-1, PGE2, and HMGB-1 by HESCs were measured using ELISA assay (R&D Systems, Minnesota, USA). Briefly, the supernatant was collected and planted in the 96-well plate along with the 5 gradient concentrations of standards. After being incubated for 90 min at room temperature, the conjugate reagents were added to be incubated for 90 min at room temperature, followed by adding the TMB solution for 15 min. Lastly, the stop solution was added and the microplate reader (BMG LABTECH, Offenburg, Germany) was utilized to measure the absorbance at 450 nm.

**Luciferase activity of NF-κB promoter**

The pNF-κB Luc reporter plasmid (Beyotime, Shanghai, China), as well as the lipofectamine 2000 (Sigma-Aldrich, California, USA), was transfected into HESCs, followed by being incubated for 48 h. The reporter activity was measured using the luciferase reporter kit (Promega, Wisconsin, USA) via determining the fluorescence intensity using a fluorescent microplate reader (BMG LABTECH, Offenburg, Germany).

**Statistical analysis**

Each experiment has been repeated three times. Data were expressed as mean ± SD and the GraphPad software was utilized for the analysis of data. The Student’s t-test was utilized to determine the difference between the 2 groups and the ANOVA method was used to analyze the difference among more than 2 groups. P < 0.05 was taken as a significant difference.

**Results**

In the present study, we aimed to clarify the potential benefit of Sitagliptin on hypoxia-induced damages in HESCs. We tested the cytotoxicity of Sitagliptin in HESCs to screen optimal concentrations used for the cell culture. Then, we measured the level of ROS and reduced GSH to investigate the effect of Sitagliptin on hypoxia-induced oxidative stress. Moreover, we examined the anti-inflammatory property of Sitagliptin by evaluating the expression of several pro-inflammatory factors. Importantly, we further assessed the involvement of p38 MAPK and the NF-κB signaling pathway to clarify the underlying mechanism.

**The cytotoxicity of Sitagliptin in HESCs**

Firstly, the optimized concentration of Sitagliptin was determined by evaluating the cytotoxicity of its different concentrations against HESCs. The HESCs were stimulated with 10, 20, 100, 200, 1000, and 2000 nM Sitagliptin for 24 hours, followed by measuring the LDH release. We found that the release of LDH (Figure 1) was maintained at around 5% as the concentration of Sitagliptin elevated from 10 to 200 nM, above which there was significantly promoted LDH release. Thus, in the subsequent experiments, 100 and 200 nM were used as the incubation concentrations of Sitagliptin in HESCs.
Sitagliptin mitigated hypoxia-induced oxidative stress in HESCs

As mentioned in the introduction, hypoxia is regarded as the main inducer for Endometriosis. HESCs were cultured in hypoxic conditions to simulate the pathological state of Endometriosis. HESCs were stimulated with Sitagliptin (100, 200) for 2 hours, followed by exposure to hypoxia for 6 hours. The level of ROS (Figure 2(a)) was found to be significantly elevated in hypoxia-stimulated HESCs, then greatly repressed by 100 and 200 nM Sitagliptin. In addition, the decreased levels of reduced GSH (Figure 2(b)) in hypoxia-treated HESCs were significantly increased by 100 and 200 nM Sitagliptin. These data collectively reveal that the hypoxia-induced oxidative stress in HESCs was ameliorated by Sitagliptin.

![Figure 1](image1.png)

**Figure 1.** The cytotoxicity of Sitagliptin in human endometrial stromal cells (HESCs). Cells were stimulated with Sitagliptin at concentrations of 10, 20, 100, 200, 1000, 2000 nM for 24 hours. Release of LDH (*, **, P < 0.05, 0.01 vs. vehicle group, n = 6).**

![Figure 2](image2.png)

**Figure 2.** Sitagliptin mitigated hypoxia-induced oxidative stress in human endometrial stromal cells (HESCs). Cells were stimulated with Sitagliptin (100, 200) for 2 hours, followed by exposure to hypoxia for 6 hours. (a) The levels of ROS; (b) The levels of reduced GSH (***, P < 0.0001 vs. vehicle group; #, ##, P < 0.05, 0.01 vs. Sitagliptin group, n = 5).**

![Figure 3](image3.png)

**Figure 3.** Sitagliptin inhibited hypoxia-induced expressions of TNF-α, IL-6, and MCP-1. Cells were stimulated with Sitagliptin (100, 200 nM) for 2 hours, followed by exposure to hypoxia for 6 hours. (a) mRNA of TNF-α, IL-6, and MCP-1; (b) Protein levels of TNF-α, IL-6, and MCP-1 as measured by ELISA (***, P < 0.0001 vs. vehicle group; #, ##, P < 0.05, 0.01 vs. Sitagliptin group, n = 6).**
Sitagliptin inhibited hypoxia-induced expressions of TNF-α, IL-6, and MCP-1 in HESCs

Excessively released inflammatory factors are reported to be involved in the pathogenesis of Endometriosis [14]. We found that the gene levels of TNF-α, IL-6, and MCP-1 (Figure 3(a)) were significantly elevated by hypoxia stimulation, then greatly downregulated by 100 and 200 nM Sitagliptin. The secretion of TNF-α (Figure 3(b)) in HESCs was dramatically increased from 123.6 pg/mL to 305.7 pg/mL by the hypoxia but greatly declined to 221.6 and 175.7 pg/mL by 100 and 200 nM Sitagliptin, respectively. The production of IL-6 in the control, hypoxia, 100, and 200 nM Sitagliptin groups was 102.5, 236.8, 162.1, and 135.2 pg/mL, respectively. In addition, the concentration of MCP-1 was significantly elevated from 87.3 pg/mL to 186.5 pg/mL in the hypoxia-treated HESCs, then greatly repressed to 132.7 and 118.8 pg/mL by 100 and 200 nM Sitagliptin, respectively. These results suggest that the severe inflammation in HESCs induced by hypoxia was significantly alleviated by Sitagliptin.

Sitagliptin reduced the expressions of COX-2 and PGE2 against hypoxia in HESCs

The synthesis of PGE2 is controlled by COX-2, which is reportedly involved in the pathogenesis of Endometriosis [5]. We found that the upregulated COX-2 (Figure 4(a-b)) in hypoxia-treated HESCs was dramatically repressed by 100 and 200 nM Sitagliptin. In addition, the secretion of PGE2 (Figure 4(c)) in HESCs was dramatically increased from 56.3 pg/mL to 166.7 pg/mL by the hypoxia, then greatly declined to 112.8 and 89.4 pg/mL by 100 and 200 nM Sitagliptin, respectively.

Sitagliptin ameliorated hypoxia-induced expression of HMGB-1 in HESCs

HMGB-1-mediated inflammation and autophagy are reportedly critical inducers for the development of Endometriosis [7]. The elevated gene level of HMGB-1 (Figure 5(a)) in hypoxia-challenged HESCs was pronouncedly suppressed by 100 and 200 nM Sitagliptin. In addition, the production of HMGB-1 was significantly elevated from 72.5 pg/mL to 155.2 pg/mL in the hypoxia-treated HESCs (Figure 5(b)), then greatly repressed to 103.4 and 79.2 pg/mL by 100 and 200 nM Sitagliptin, respectively.

Sitagliptin prevented hypoxia-induced activation of p38 MAPK in HESCs

The p38 MAPK pathway regulates the progression of Endometriosis [15]. We found that the expression ratio of p-p38/p38 (Figure 6) was significantly promoted in hypoxia-treated HESCs, and greatly inhibited by 100 and 200 nM Sitagliptin, indicating an effective inhibitory effect of Sitagliptin against the p38 MAPK pathway.

Sitagliptin attenuated hypoxia-induced phosphorylation and degradation of IκBa

IκBa is a natural inhibitor of NF-κB and its phosphorylation and degradation contribute to the activation of NF-κB [16]. The increased expression level of p-IκBa and declined expression level of total IκBa (Figure 7) in hypoxia-treated HESCs were found to be dramatically reversed by 100 and 200 nM Sitagliptin, indicating a potential inhibitory effect of Sitagliptin against NF-κB activation.

Sitagliptin prevented hypoxia-induced activation of NF-κB in HESCs

To further explore the inhibitory effect of Sitagliptin against NF-κB activation, the nuclear level of NF-κB p65 and the activity of the NF-κB promoter were evaluated. We found that the upregulated NF-κB p65 in the nuclei (Figure 8(a)) and increased luciferase activity of the NF-κB promoter (Figure 8(b)) in hypoxia-treated HESCs were pronouncedly abolished by 100 and 200 nM Sitagliptin, indicating an effective inhibitory effect of Sitagliptin against NF-κB activation.

Discussion

Although Endometriosis has become a common disease, its pathogenesis is still perplexing. Recent studies have shown that inflammatory response is
Sitagliptin reduced the expression of COX-2 and PGE₂ against hypoxia. Cells were stimulated with Sitagliptin (100, 200 nM) for 2 hours, followed by exposure to hypoxia for 6 hours. (a) mRNA of COX-2; (b) Protein of COX-2; (c) Secretions of PGE₂ (***, P < 0.0001 vs. vehicle group; #, ##, P < 0.05, 0.01 vs. Sitagliptin group, n = 6).

Figure 4.

an important part of the progression and development of Endometriosis. Therefore, it is necessary to find drugs that can exert anti-inflammatory effects for the treatment of Endometriosis. In the current study, we investigated the potential effects of Sitagliptin, a DDP-4 inhibitor, on an in vitro hypoxia-induced endometriosis model. We found that treatment with Sitagliptin inhibited hypoxia-induced damages in HESCs. In brief, Sitagliptin suppressed the expressions of the pro-inflammatory cytokines including TNF-α, IL-6, and MCP-1. Sitagliptin also significantly reduced hypoxia-induced oxidative stress. In addition, Sitagliptin inhibited the expressions of COX-2, PGE₂, and HMGB-1. Mechanistically, we found that Sitagliptin mitigated the activation of the p-38 MAPK and NF-kB pathways.

COX-2 is a kind of membrane binding protein and is mainly distributed in microsomes of mammalian cells. It is the functional target of non-steroidal anti-inflammatory drugs (NSAIDs) and the important rate-limiting enzyme for the synthesis of prostaglandin [17]. COX-2 is regularly mainly expressed in renal tissues and the central nervous system. However, its expression level can be induced by external or internal stimuli, such as growth factors, inflammatory factors, and oncoproteins. The upregulation of COX-2 is reportedly closely associated with the development of inflammation, pain, and degenerative diseases of the nervous system [18]. It is widely reported that PGE₂, which is mainly catalyzed by COX-2, is an important inflammatory mediator involved in multiple cellular progressions, including cell proliferation, apoptosis, immunological surveillance, and inflammation [19]. Tamura reported that IL-1 stimulation could elevate the expression level of COX-2 in the endometrial tissues, and subsequently facilitate the synthesis of PGE₂ resulting in the elevated expression level of vascular endothelial growth factor (VEGF). The vascular endothelial permeability was enhanced and the vascular endothelial cell deformation and migration facilitated, which ultimately induced angiogenesis and finally, the planting and growth of ectopic endometrium [20]. We found that the activated COX-2/PGE₂ axis in HESCs induced by hypoxia was significantly reversed by Sitagliptin,
Figure 5. Sitagliptin ameliorated hypoxia-induced expression of HMGB-1 in human endometrial stromal cells (HESCs). Cells were stimulated with Sitagliptin (100, 200 nM) for 2 hours, followed by exposure to hypoxia for 6 hours. (a). mRNA of HMGB-1; (b). Secretions of HMGB-1 (****, P < 0.0001 vs. vehicle group; #, ##, P < 0.05, 0.01 vs. Sitagliptin group, n = 5).

Figure 6. Sitagliptin prevented hypoxia-induced activation of p38 MAPK in human endometrial stromal cells (HESCs). Cells were stimulated with Sitagliptin (100, 200 nM) for 2 hours, followed by exposure to hypoxia for 6 hours. P-p38 and total p38 were measured by Western blot analysis (****, P < 0.0001 vs. vehicle group; #, ##, P < 0.05, 0.01 vs. Sitagliptin group, n = 5).

Figure 7. Sitagliptin attenuated hypoxia-induced phosphorylation and degradation of IκBα. Cells were stimulated with Sitagliptin (100, 200 nM) for 2 hours, followed by exposure to hypoxia for 6 hours. p-IκBα and total IκBα (****, P < 0.0001 vs. vehicle group; #, ##, P < 0.05, 0.01 vs. Sitagliptin group, n = 5).
indicating that Sitagliptin might be an effective agent for the treatment of Endometriosis by suppressing the COX-2/PGE2 axis-mediated inflammation. This was further verified by the declined production of inflammatory factors in hypoxia-treated HESCs after the treatment with Sitagliptin. HMGB-1 is recently reported to be an important inflammatory mediator [21] and oxidative stress is regarded as the inducer for significant inflammation in damaged cells [22]. The anti-inflammatory effects of Sitagliptin were further verified by the ameliorated oxidative stress and declined production of HMGB-1 in hypoxia-treated HESCs after the treatment with Sitagliptin.

Seval [23] reported in 17β-E2-stimulated HESCs, the activation of the p38 MAPK pathway in 10 min. In addition, the production and expressions of multiple types of inflammatory mediators, such as IL-6, IL-8, MCP-1, and COX-2, were found to be significantly elevated by the activation of the p38 MAPK pathway [24]. Recently, the involvement of the p38 MAPK pathway in the development and processing of Endometriosis is widely reported [25,26]. We found that the activated p38 MAPK pathway was significantly suppressed by Sitagliptin, accompanied by the decreased production of inflammatory mediators, indicating that Sitagliptin might alleviate the inflammation in hypoxia-treated HESCs by mediating the p38 MAPK pathway. In future work, the regulatory effects of Sitagliptin on p38 MAPK pathway-mediated inflammation will be further identified by introducing a specific agonist of the p38 MAPK pathway.

NF-κB is an important inflammatory transcriptional factor that facilitates the production of multiple inflammatory factors [27]. Regularly, NF-κB (p65/p50) and I-κB bind together to form a trimer complex to prevent NF-κB from entering the nucleus. However, following internal or external stimuli, I-κB is phosphorylated and degraded by the signals delivered from the receptors, which further contributes to the phosphorylation of p65 and the exposure of nuclear localization sequence. NF-κB p65 is then quickly moved into the nucleus and facilitates the expression of target inflammatory factors by binding with promoters [28]. Recently, the NF-κB pathway has been widely identified as an important pathological mechanism for the development and progression of Endometriosis [29,30]. We found that Sitagliptin significantly repressed the phosphorylation and degradation of IκBα and decreased the transcriptional activity of NF-κB in the nucleus, indicating a promising inhibitory effect of Sitagliptin against the activated NF-κB pathway in hypoxia-treated HESCs. In our future work, the regulatory effects of Sitagliptin on NF-κB-mediated inflammation will be further identified by introducing a specific agonist of the NF-κB pathway.

DPP-4 inhibitors have been widely used for the treatment of type II diabetes since 2006. However, a large number of studies have demonstrated that DPP-4 also plays an important role in other diseases. In 2005, Kruschinski C et al. showed evidence that inhibition of DPP-4 could directly reduce airway inflammation in a rat asthma model, suggesting that DPP-4 inhibitors might have therapeutic benefits to the escalating burden of asthma and airway inflammation [31]. A recent study in 2018 displayed that overexpression of DPP-4 secreted by the liver promotes inflammatory response in visceral adipose tissue and insulin resistance [32]. Moreover, previous studies have
indicated that DPP-4 inhibitors, including Sitagliptin, exert significant anti-inflammatory actions in both in vivo and in vitro models [33,34]. Our study shows new evidence to clarify the anti-inflammatory effects of Sitagliptin on hypoxia-induced inflammation in an Endometriosis model. Notably, several effective drugs in treating the symptoms of endometriosis have displayed similar anti-inflammatory capacities to Sitagliptin. For example, the administration of Caulis Sargentodoxae decreased serum levels of inflammatory cytokines including IL-1, IL-2, IL-6, TNF-α, and PGE₂ [35]. Recently, Genovese T reported that combined fotemustine and dexamethasone therapy could suppress the inflammatory response in an in vivo Endometriosis model by inhibiting NF-κB and p38 MAPK pathway [36].

**Conclusion**

In this study, we tested the promising therapeutic effect of Sitagliptin on an in vitro model. Our results show that Sitagliptin could ameliorate hypoxia-induced oxidative stress in hESCs. Furthermore, Sitagliptin treatment inhibited the expression of pro-inflammatory cytokines and suppressed the COX-2/PGE₂ axis. Importantly, the protective effects of Sitagliptin are mediated through inhibition of the p38 MAPK and NF-κB signaling pathways. Taken together, our findings indicate that Sitagliptin possesses comprehensive benefits in hypoxia-challenged hESCs, indicating a conceivable implication in Endometriosis treatment.

**Acknowledgements**

We acknowledge “The First Affiliated Hospital of Jinzhou Medical University”.

**Disclosure statement**

No potential conflict of interest was reported by the author(s).

**Funding**

This work was supported by the The First Affiliated Hospital of Jinzhou Medical University;

**Ethical statements**

The protocols used in this study were approved by the Ethical Committee of Jinzhou Medical University.

**Consent to publication**

All the authors agreed to publish this article.

**Data availability statement**

The data that support the findings of this study are available from the corresponding author upon reasonable request.

**Author contribution**

Ying Li and Zhili Jin designed the study. Ying Li, Xiaolin Lv, and Mei Jiang performed the experiments and collected the data. Ying Li contributed materials/analysis tools. Zhili Jin wrote and revised the paper. All authors have reviewed the manuscript.

**References**

[1] Czyzyk A, Podligurna A, Szellig A, et al. Update on endometriosis pathogenesis. Minerva Ginecol. 2017;69:447–461.

[2] Sampson JA. Metastatic or embolic endometriosis, due to the menstrual dissemination of endometrial tissue into the venous circulation. Am J Pathol. 1927;3(93–110):43.

[3] Qi Q, Liu X, Zhang Q, et al. Platelets induce increased estrogen production through NF-kappaB and TGF-beta1 signaling pathways in endometriotic stromal cells. Sci Rep. 2020;10:1281.

[4] Chen PS, Chiu WT, Hsu PL, et al. Pathophysiological implications of hypoxia in human diseases. J Biomed Sci. 2020;27:63.

[5] Lai ZZ, Yang HL, Ha SY, et al. Cyclooxygenase-2 in endometriosis. Int J Biol Sci. 2019;15:2783–2797.

[6] Wu MH, Lin SC, Hsiao KY, et al. Hypoxia-inhibited dual-specificity phosphatase-2 expression in endometriotic cells regulates cyclooxygenase-2 expression. J Pathol. 2011;225:390–400.

[7] Huang J, Chen X, Lv Y. HMGB1 mediated inflammation and autophagy contribute to endometriosis. Front Endocrinol (Lausanne). 2021;12:616696.

[8] Scutiero G, Iannone P, Bernardi G, et al. Oxidative stress and endometriosis: a systematic review of the literature. Oxid Med Cell Longev. 2017;2017:7265238.

[9] Scott LJ. Sitagliptin: a review in type 2 diabetes. Drugs. 2017;77:209–224.

[10] Chen LY, Zhang DL, Yu L, et al. MIAT reduces apoptosis of cardiomyocytes after ischemia/reperfusion injury. Bioengineered. 2019;10(1):121–132.
[11] Zhang BH, Hao ZW, Zhou WL, et al. Formononetin protects against ox-LDL-induced endothelial dysfunction by activating PPAR-y signaling based on network pharmacology and experimental validation. Bioengineered. 2021;12(1):4887–4898.

[12] Beutler E, Duron O, Kelly BM. Improved method for the determination of blood glutathione. J Lab Clin Med. 1963;61:882–888.

[13] Wang X, Li TZ. Ropivacaine inhibits the proliferation and migration of colorectal cancer cells through ITGB1. Bioengineered. 2021;12(1):44–53.

[14] Chiavarino F, Cipriani S, Ricci E, et al. Endometriosis and inflammatory bowel disease: a systematic review of the literature. Eur J Obstet Gynecol Reprod Biol. 2020;252:246–251.

[15] Wu R, Zhou W, Chen S, et al. Lipoxin A4 suppresses the development of endometriosis in an ALX receptor-dependent manner via the p38 MAPK pathway. Br J Pharmacol. 2014;171:4927–4940.

[16] Stancovski I, Baltimore D. NF-kappaB activation: the I kappaB kinase revealed? Cell. 1997;91:299–302.

[17] Yao C, Narumiya S. Prostaglandin-cytokine crosstalk in chronic inflammation. Br J Pharmacol. 2019;176:337–354.

[18] Martin-Sanz P, Mayoral R, Casado M, et al. COX-2 in liver, from regeneration to hepatocarcinogenesis: what we have learned from animal models? World J Gastroenterol. 2010;16:1340–1345.

[19] Harizi H. Reciprocal crosstalk between dendritic cells and natural killer cells under the effects of PGE2 in immunity and immunopathology. Cell Mol Immunol. 2013;10:213–221.

[20] Tamura M, Sebastian S, Yang S, et al. Interleukin-1beta elevates cyclooxygenase-2 protein level and enzyme activity via increasing its mRNA stability in human endometrial stromal cells: an effect mediated by extracellularly regulated kinases 1 and 2. J Clin Endocrinol Metab. 2002;87:3263–3273.

[21] Nogueira-Machado JA, de Oliveira Volpe CM. HMGB-1 as a target for inflammation controlling. Recent Pat Endocr Metab Immune Drug Discov. 2012;6:201–209.

[22] Guzik TJ, Touyz RM. Oxidative stress, inflammation, and vascular aging in hypertension. Hypertension. 2017;70:660–667.

[23] Seval Y, Cakmak H, Kayisi UA, et al. Estrogen-mediated regulation of p38 mitogen-activated protein kinase in human endometrium. J Clin Endocrinol Metab. 2006;91:2349–2357.

[24] Lee DH, Kim SC, Joo JK, et al. Effects of 17beta-estradiol on the release of monocyte chemotactic protein-1 and MAPK activity in monocytes stimulated with peritoneal fluid from endometriosis patients. J Obstet Gynecol Res. 2012;38:516–525.

[25] Cakmak H, Seval-Celik Y, Arlier S, et al. p38 mitogen-activated protein kinase is involved in the pathogenesis of endometriosis by modulating inflammation, but not cell survival. Reprod Sci. 2018;25:587–597.

[26] Liu Y, Ma J, Cui D, et al. LncRNA MEG3-210 regulates endometrial stromal cells migration, invasion and apoptosis through p38 MAPK and PKA/ ERK1/2 signalling via interaction with Galectin-1 in endometriosis. Mol Cell Endocrinol. 2020;513:110870.

[27] Diskin T, Tal-Or P, Erlich S, et al. Closed head injury induces upregulation of Belrin 1 at the cortical site of injury. J Neurotrauma. 2005;22:750–762.

[28] Qiu J, Grafe MR, Schmura SM, et al. Differential NF-kappa B regulation of bcl-x gene expression in hippocampus and basal forebrain in response to hypoxia. J Neurosci Res. 2001;64:223–234.

[29] Kaponis A, Iwabe T, Taniguchi F, et al. The role of NF-kappaB in endometriosis. Front Biosci (Schol Ed). 2012;4:1213–1234.

[30] Yu J, Chen LH, Zhang B, et al. The modulation of endometriosis by lncRNA MALAT1 via NF-kappaB/iNOS. Eur Rev Med Pharmacol Sci. 2019;23:4073–4080.

[31] Kruschinski C, Skripuletz T, Bedoui S, et al. CD26 (dipeptidyl-peptidase IV)-dependent recruitment of T cells in a rat asthma model. Clin Exp Immunol. 2005;139(1):17–24.

[32] Ghorpade DS, Ozcan L, Zheng Z, et al. Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance. Nature. 2018;555 (7698):673–677.

[33] He Y, Yang G, Yao F, et al. Sitagliptin inhibits vascular inflammation via the SIRT6-dependent signaling pathway. Int Immunopharmacol. 2019;75:105805.

[34] Xu L, Ren Y. Sitagliptin inhibits cell apoptosis and inflammation of renal tissues in diabetic nephropathy model rats. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2019;35:217–222.

[35] Zhuang M, Cao Y, Shi Y, et al. Caulis sagittadotoxae prescription plays a therapeutic role with decreased inflammatory cytokines in peritoneal fluid in the rat endometriosis model. Evid Based Complement Alternat Med. 2020;2020:9627907.

[36] Genovese T, Siracusa R, D’Amico R, et al. Regulation of inflammatory and proliferative pathways by fote-mustine and dexamethasone in endometriosis. Int J Mol Sci. 2021;22(11):5998.